KPV is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
KPV (Lysine-Proline-Valine tripeptide) is researched primarily for anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation. The only α-MSH fragment with pure NF-κB inhibition independent of melanocortin receptors — oral bioavailability makes it uniquely practical for gut-targeted anti-inflammatory use. It belongs to the Alpha-MSH fragment, NF-κB inhibitor category of compounds.
What Is KPV?
KPV (Lysine-Proline-Valine tripeptide) is a Alpha-MSH fragment, NF-κB inhibitor. C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), naturally occurring from proteolytic cleavage.
The only α-MSH fragment with pure NF-κB inhibition independent of melanocortin receptors — oral bioavailability makes it uniquely practical for gut-targeted anti-inflammatory use. It has attracted significant research interest for its potential effects on anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.
How Does KPV Produce These Benefits?
Inhibits nuclear factor-kappa B (NF-κB) activation through PepT1 transporter-mediated cellular uptake, completely independent of melanocortin receptors. Blocks NF-κB nuclear import and suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at nanomolar concentrations. Also inhibits MAPK inflammatory signaling cascade.
This multi-pathway activity is why KPV shows potential across several different applications rather than being limited to a single use case.
Can KPV Help With Anti-Inflammatory?
Research suggests KPV may support anti-inflammatory through its alpha-msh fragment, nf-κb inhibitor activity. Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
Protocols targeting anti-inflammatory typically use 200-500 mcg daily administered once or twice daily for 4-8 weeks.
Can KPV Help With Ibd Reduction?
Research suggests KPV may support IBD reduction through its alpha-msh fragment, nf-κb inhibitor activity. Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
Protocols targeting IBD reduction typically use 200-500 mcg daily administered once or twice daily for 4-8 weeks.
Can KPV Help With Intestinal Barrier Repair?
Research suggests KPV may support intestinal barrier repair through its alpha-msh fragment, nf-κb inhibitor activity. Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
Protocols targeting intestinal barrier repair typically use 200-500 mcg daily administered once or twice daily for 4-8 weeks.
Can KPV Help With Skin Inflammation Reduction?
Research suggests KPV may support skin inflammation reduction through its alpha-msh fragment, nf-κb inhibitor activity. Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
Protocols targeting skin inflammation reduction typically use 200-500 mcg daily administered once or twice daily for 4-8 weeks.
Can KPV Help With Immune Modulation?
Research suggests KPV may support immune modulation through its alpha-msh fragment, nf-κb inhibitor activity. Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
Protocols targeting immune modulation typically use 200-500 mcg daily administered once or twice daily for 4-8 weeks.
Can Stacking Enhance KPV Benefits?
Pairs synergistically with BPC-157 for comprehensive gut healing — KPV handles inflammation through NF-κB while BPC-157 promotes tissue repair through growth factor pathways.
See our KPV stacking guide for detailed combination protocols.
What Is the Bottom Line on KPV Benefits?
KPV is researched for anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation. The evidence base includes: Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
KPV is not fda-approved. expected to move from fda category 2 to category 1 (allowing licensed compounding) based on 2026 regulatory developments. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
KPV : Benefits, Dosage, Side Effects & Research
Related Reading
- KPV Dosage Guide
- KPV Side Effects
- KPV Stacking Guide
- KPV Cycle Guide
- KPV Research
- BPC-157 Complete Guide
Calculate Your KPV Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for KPV.
Open Calculator →Research-Grade Sourcing
If you're going to research KPV, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is KPV?
KPV (Lysine-Proline-Valine tripeptide) is a Alpha-MSH fragment, NF-κB inhibitor. C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), naturally occurring from proteolytic cleavage. It is researched for anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.
What is the recommended KPV dosage?
Common dosages: 200-500 mcg daily administered once or twice daily via oral (most studied), intranasal, subcutaneous. Cycle length: 4-8 weeks. Half-life: not published. Use our peptide calculator for exact reconstitution math.
What are the side effects of KPV?
No serious adverse events in preclinical studies. Theoretical potential for immune suppression at very high doses given NF-κB inhibition. GI upset possible with oral administration.
Is KPV safe?
KPV has shown a preliminary safety profile in research. Not FDA-approved. Expected to move from FDA Category 2 to Category 1 (allowing licensed compounding) based on 2026 regulatory developments. All research should follow appropriate safety protocols.